Australia’s first true biotech incubator

Early-stage investment in Australian medical biotechnology, from pre-clinical research to commercialisation.

Medical innovation, funding, and pre-clinical research with strong financial returns.

From early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.

We know first hand how to build world-class companies. Proto Axiom on-shores scientific capacity backed by leading institutional investors to keep IP in Australia.

Endo Axiom (Endo) is a cutting-edge platform technology harnessing liver-specific nanoparticles, set to revolutionise diabetes treatment.

Established by esteemed academics from the University of Sydney and Sydney Local Health District, Endo Axiom secured a $2.2 million investment from Proto Axiom. As a proud member of the Proto Axiom family, Endo benefits from comprehensive commercial, technical, and financial support from Proto.

Dr. Nicholas Hunt, CEO of Endo, holds a Senior Lecturer position at Concord Clinical School and is a recipient of the MRFF Targeted Translation Research Accelerator (TTRA) and Sydney Research Accelerator (SOAR) awards. Joining him in this venture are co-founders Prof. David Le Couteur AO and Prof. Victoria Cogger, with Lawrence Gozlan presiding as Chairman.

Dr. Nicholas Hunt
CEO and Co-founder

Australia produces world leading intellectual property in drug development and medical devices, yet captures virtually none of the downstream economics and job multipliers.

Proto Axiom on shores capacity, keeping Australian IP in Australia.